Frequently Asked Questions about Novo Nordisk A/S (NVO)

Name: Novo Nordisk A/S (NVO) Institutional Financial Dataset
Creator: Olyth
License: https://olyth.xyz

Question 1

What does Novo Nordisk A/S (NVO) do?

Accepted Answer

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obe...

Question 2

Is Novo Nordisk A/S (NVO) a good stock to buy?

Accepted Answer

Olyth's institutional analysis of NVO reveals an Altman Z-Score of 3.67 and a Piotroski F-Score of 6/9. These metrics, combined with its 5-year revenue trend ($297.20B most recent), help investors decide if NVO fits their risk profile.

Question 3

What is the current P/E ratio for NVO?

Accepted Answer

As of the latest trading session, Novo Nordisk A/S (NVO) has a trailing P/E ratio of 10.20.

Question 4

Who is the CEO of Novo Nordisk A/S?

Accepted Answer

The current Chief Executive Officer of Novo Nordisk A/S is Maziar Mike Doustdar.

Question 5

What was NVO's revenue for the last 5 years?

Accepted Answer

According to its latest income statements, Novo Nordisk A/S reported annual revenues of $297.20B (2025), $290.40B (2024), $232.26B (2023), $176.95B (2022), $140.80B (2021) respectively.

Question 6

Does NVO pay a dividend?

Accepted Answer

Novo Nordisk A/S currently pays a dividend to its shareholders, with a trailing dividend yield of 5.00%.

Question 7

How much debt and cash flow does NVO have?

Accepted Answer

In its latest reporting period, Novo Nordisk A/S generated $28.99B in Free Cash Flow against a total debt load of $130.96B.

Question 8

What is the Price-to-Book (P/B) ratio of Novo Nordisk A/S?

Accepted Answer

The Price-to-Book (P/B) ratio for Novo Nordisk A/S (NVO) is currently 5.38.

Question 9

What is the Price-to-Sales (P/S) ratio of NVO?

Accepted Answer

Based on trailing twelve-month data, Novo Nordisk A/S (NVO) trades at a Price-to-Sales (P/S) ratio of 3.38.

Question 10

What is Novo Nordisk A/S's Return on Equity (ROE)?

Accepted Answer

Novo Nordisk A/S (NVO) has a Return on Equity (ROE) of 61.10%, representing its profitability relative to shareholder equity.

Period	Operating CF	SBC	CapEx	Free CF	True FCF
2025-12	119.1B	0	-90.1B	29B	29B
2024-12	121B	2.3B	-51.3B	69.7B	67.4B
2023-12	108.9B	2.1B	-38.9B	70B	67.9B
2022-12	78.9B	1.5B	-14.8B	64.1B	62.6B
2021-12	55B	1B	-7.4B	47.6B	46.6B

Period	Operating CF	SBC	CapEx	Free CF	True FCF
2025-12	119.1B	0	-90.1B	29B	29B
2024-12	121B	2.3B	-51.3B	69.7B	67.4B
2023-12	108.9B	2.1B	-38.9B	70B	67.9B
2022-12	78.9B	1.5B	-14.8B	64.1B	62.6B
2021-12	55B	1B	-7.4B	47.6B	46.6B